Franco-Canadian start-up Angany claims to be “gaining momentum” for its plant-based immunotherapy platform.
The firm aims to leverage the immunogenicity and safety profile of its plant-based eBioparticle technology for the development of therapeutic vaccines. Angany is working in both the human pharma and animal health sectors. It is targeting applications in allergy, autoimmune diseases, chronic inflammation and cancer.
The Québec-based company’s initial product candidates for human medicine are vaccines against cat allergy and peanut allergy. The first of these is scheduled to enter clinical development in the second half of 2022. Angany is also working in degenerative disease and oncology for veterinary indications.
The immunotherapy platform is based on a family of proprietary synthetic enveloped bioparticles that show a strong immunomodulatory potency. Angany said this “unique auto-adjuvanted antigen presentation platform has successfully demonstrated the capacity to elicit protective/neutralizing immune responses against allergens and self-proteins”.
The company recently presented its eBioparticle system at the BIO International Convention in San Diego, California. It is aiming to build on the “significant attention from major players in the pharma and animal health markets” shown to its technology platform. Angany is partnering with Canadian consultancy LEVOYA to further discussions with potential animal health partners.
The start-up is also preparing a series B investment round of Can$35 million ($27 million) to finance upcoming clinical development. It said it is discussing terms with potential candidates to lead the round.
Last year, Angany partnered with Nextmune for the development of canine atopic dermatitis product candidates.
Analyst Contact Details: Joseph Harvey
